C Jameson

Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.

R. Eeles, Z. Kote-Jarai, D. Easton, 2009, Oncology reports.

LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression

A E Willis, H. Gabra, M. Mura, 2014, Oncogene.

The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer.

J van der Meulen, M Emberton, S Charman, 2015, Contemporary clinical trials.